Journal of the American Academy of Dermatology
Volume 61, Issue 5 , Pages 819-828 , November 2009

Lymphatic invasion detected by D2-40/S-100 dual immunohistochemistry does not predict sentinel lymph node status in melanoma

  • Matthew Petitt, DO

      Affiliations

    • Department of Dermatology, University of Texas Medical Branch, Galveston, Texas
    • ,
  • Ashley Allison, MD

      Affiliations

    • Department of Dermatology, University of Texas Medical Branch, Galveston, Texas
    • ,
  • Tally Shimoni, BS

      Affiliations

    • University of Texas Medical Branch School of Medicine, Galveston, Texas
    • ,
  • Tatsuo Uchida, MS

      Affiliations

    • Office of Biostatistics, University of Texas Medical Branch, Galveston, Texas
    • ,
  • Sharon Raimer, MD

      Affiliations

    • Department of Dermatology, University of Texas Medical Branch, Galveston, Texas
    • ,
  • Brent Kelly, MD

      Affiliations

    • Department of Dermatology, University of Texas Medical Branch, Galveston, Texas
    • Corresponding Author InformationReprint requests: Brent Kelly, MD, Department of Dermatology, University of Texas Medical Branch, 301 University Blvd, Galveston, TX 77555-0783.

References 

  1. Balch CM, Buzaid AC, Soong SJ, Atkins MB, Cascinelli N, Coit DG, et al. Final version of the American Joint Committee on Cancer staging system for cutaneous melanoma. J Clin Oncol. 2001;19:3635–3648
  2. Balch CM, Soong SJ, Gershenwald JE, Thompson JF, Reintgen DS, Cascinelli N, et al. Prognostic factors analysis of 17,600 melanoma patients: validation of the American Joint Committee on Cancer melanoma staging system. J Clin Oncol. 2001;19:3622–3634
  3. Statius Muller MG, van Leeuwen PAM, de Lange-de Klerk ESM, van Diest PJ, Pijpers R, Ferwerda CC, et al. The sentinel lymph node status is an important factor for predicting clinical outcome in patients with stage I or II cutaneous melanoma. Cancer. 2001;91:2401–2408
  4. Gershenwald JE, Thompson W, Mansfield PF, Lee JE, Colome MI, Tseng C, et al. Multi-institutional melanoma lymphatic mapping experience: the prognostic value of sentinel lymph node status in 612 stage I or II melanoma patients. J Clin Oncol. 1999;17:976–983
  5. Yee VS, Thompson JF, McKinnon JG, Scolyer RA, Li LX, McCarthy WH, et al. Outcome in 846 cutaneous melanoma patients from a single center after a negative sentinel node biopsy. Ann Surg Oncol. 2005;12:429–439
  6. Jansen L, Nieweg OE, Peterse JL, Hoefnagel CA, Olmos RA, Kroon BB. Reliability of sentinel lymph node biopsy for staging melanoma. Br J Surg. 2000;87:484–489
  7. Leong SP, Kashani-Sabet M, Desmond RA, Kim RP, Nguyen DH, Iwanaga K, et al. Clinical significance of occult metastatic melanoma in sentinel lymph nodes and other high-risk factors based on long-term follow-up. World J Surg. 2005;29:683–691
  8. Koskivuo I, Talve L, Vihinen P, Maki M, Vahlberg T, Suominen E. Sentinel lymph node biopsy in cutaneous melanoma: a case-control study. Ann Surg Oncol. 2007;14:3566–3574
  9. Landi G, Polverelli M, Moscatelli G, Landi C, Fiscelli O, Erbazzi A. Sentinel lymph node biopsy in patients with primary cutaneous melanoma: study of 455 cases. J Eur Acad Dermatol Venereol. 2000;14:35–45
  10. Morton DL, Thompson JF, Cochran AJ, Mozzillo N, Elashoff R, Essner R, et al. Sentinel-node biopsy or nodal observation in melanoma. N Engl J Med. 2006;355:1307–1317
  11. Balch CM, Cascinelli N. Sentinel-node biopsy in melanoma. N Engl J Med. 2006;355:1370–1371
  12. Kretschmer L, Hilgers R, Mohrle M, Balda BR, Breuninger H, Konz B, et al. Patients with lymphatic metastasis of cutaneous malignant melanoma benefit from sentinel lymphadenectomy and early excision of their nodal disease. Eur J Cancer. 2004;40:212–218
  13. Rutkowski P, Nowecki ZI, Nasierowska-Guttmejer A, Ruka W. Lymph node status and survival in cutaneous malignant melanoma-sentinel lymph node biopsy impact. Eur J Surg Oncol. 2003;29:611–618
  14. Nowecki ZI, Rutkowski P, Michej W. The survival benefit to patients with positive sentinel node melanoma after completion lymph node dissection may be limited to the subgroup with a primary lesion Breslow thickness greater than 1.0 and less than or equal to 4 mm (pT2-pT3). Ann Surg Oncol. 2008;15:2223–2234
  15. Wright BE, Scheri RP, Ye X, Faries MB, Turner RR, Essner R, et al. Importance of sentinel lymph node biopsy in patients with thin melanoma. Arch Surg. 2008;143:892–899
  16. Karakousis GC, Gimotty PA, Czerniecki BJ, Elder DE, Elenitsas R, Ming ME, et al. Regional nodal metastatic disease is the strongest predictor of survival in patients with thin vertical growth phase melanomas: a case for SLN staging biopsy in these patients. Ann Surg Oncol. 2007;14:1596–1603
  17. Dessureault S, Soong SJ, Ross MI, Thompson JF, Kirkwood JM, Coit DG, et al. Improved staging of node-negative patients with intermediate to thick melanomas (>1 mm) with the use of lymphatic mapping and sentinel lymph node biopsy. Ann Surg Oncol. 2001;8:766–770
  18. Zapas JL, Coley HC, Beam SL, Brown SD, Jablonski KA, Elias EG. The risk of regional lymph node metastases in patients with melanomas less than 1.0 mm thick: recommendations for sentinel lymph node biopsy. J Am Coll Surg. 2003;197:403–407
  19. Stitzenberg KB, Groben PA, Stern SL, Thomas NE, Hensing TA, Sansbury LB, et al. Indications for lymphatic mapping and sentinel lymphadenectomy in patients with thin melanoma (Breslow thickness < or =1.0 mm). Ann Surg Oncol. 2004;11:900–906
  20. Carlson GW, Murray DR, Hestley A, Staley CA, Lyles RH, Cohen C. Sentinel lymph node mapping for thick (>or=4-mm) melanoma: should we be doing it?. Ann Surg Oncol. 2003;10:408–415
  21. Kesmodel SB, Karakousis GC, Botbyl JD, Canter RJ, Lewis RT, Wahl PM, et al. Mitotic rate as a predictor of sentinel lymph node positivity in patients with thin melanomas. Ann Surg Oncol. 2005;12:449–458
  22. Lens MB, Dawes M, Newton-Bishop JA, Goodacre T. Tumor thickness as a predictor of occult lymph node metastases in patients with stage I and II melanoma undergoing sentinel lymph node biopsy. Br J Surg. 2002;89:1223–1227
  23. Rousseau DL, Ross MI, Johnson MM, Prieto VG, Lee JE, Mansfield PF, et al. Revised American Joint Committee on Cancer staging criteria accurately predict sentinel lymph node positivity in clinically node-negative melanoma patients. Ann Surg Oncol. 2003;10:569–574
  24. Nguyen CL, McClay EF, Cole DJ, O'Brien PH, Gillanders WE, Metcalf JS, et al. Melanoma thickness and histology predict sentinel lymph node status. Am J Surg. 2001;181:8–11
  25. Mraz-Gernhard S, Sagebiel RW, Kashani-Sabet M, Miller JR, Leong SPL. Prediction of sentinel lymph node micrometastasis by histologic features in primary cutaneous malignant melanoma. Arch Dermatol. 1998;134:983–987
  26. Pagnanelli G, Bono R, Pizzichetta MA, Talamini R, Ascierto PA, Testori A, et al. Clinical and dermoscopic criteria related to melanoma sentinel lymph node positivity. Anticancer Res. 2007;27:2939–2944
  27. Kaur C, Thomas RJ, Desai N, Green MA, Lovell D, Powell BW, et al. The correlation of regression in primary melanoma with sentinel lymph node status. J Clin Pathol. 2008;61:297–300
  28. Karakousis GC, Gimotty PA, Botbyl JD, Kesmodel SB, Elder DE, Elenitsas R, et al. Predictors of regional nodal disease in patients with thin melanomas. Ann Surg Oncol. 2006;13:533–541
  29. Liszkay G, Orosz Z, Peley G, Csuka O, Plotar V, Sinkovics I, et al. Relationship between sentinel lymph node status and regression in primary malignant melanoma. Melanoma Res. 2005;15:509–513
  30. Wagner JD, Gordon MS, Chuang TY, Coleman JJ, Hayes JT, Jung SH, et al. Predicting sentinel and residual lymph node basin disease after sentinel lymph node biopsy for melanoma. Cancer. 2000;89:453–462
  31. Cuellar FA, Vilalta A, Rull R, Vidal-Sicart S, Palou J, Ventura PJ, et al. Small cell melanoma and ulceration as predictors of positive sentinel lymph node in malignant melanoma patients. Melanoma Res. 2004;14:277–282
  32. Wong SL, Katten MW, McMasters KM, Coit DG. A nomogram that predicts the presence of sentinel node metastasis in melanoma with better discrimination than the American Joint Committee on Cancer staging system. Ann Surg Oncol. 2005;12:282–288
  33. Paek SC, Griffith KA, Johnson TM, Sondak VK, Wong SL, Chang AE, et al. The impact of factors beyond Breslow depth on predicting sentinel lymph node positivity in melanoma. Cancer. 2007;109:100–108
  34. Sondak VK, Taylor JM, Sabel MS, Wang Y, Lowe L, Grover AC, et al. Mitotic rate and younger age are predictors of sentinel lymph node positivity: lessons learned from the generation of a probabilistic model. Ann Surg Oncol. 2004;11:247–258
  35. Gershenwald JE, Fidler IJ. Targeting lymphatic metastasis. Science. 2002;296:1811–1812
  36. Rinderknecht M, Detmar M. Tumor lymphangiogenesis and melanoma metastasis. J Cell Physiol. 2008;216:346–354
  37. Hirakawa S, Detmar M. New insights into the biology and pathology of the cutaneous lymphatic system. J Dermatol Sci. 2004;35:1–8
  38. Shields JD, Borsetti M, Rigby H, Harper SJ, Mortimer PS, Levick JR, et al. Lymphatic density and metastatic spread in human malignant melanoma. Br J Cancer. 2004;90:693–700
  39. Massi D, Puig S, Franchi A, Malvehy J, Vidal-Sicart S, Gonzalez-Cao M, et al. Tumour lymphangiogenesis is a possible predictor of sentinel lymph node status in cutaneous melanoma: a case-control study. J Clin Pathol. 2006;59:166–173
  40. Dadras SS, Paul T, Bertoncini J, Brown LF, Muzikansky A, Jackson DG, et al. Tumor lymphangiogenesis: a novel prognostic indicator for cutaneous melanoma metastasis and survival. Am J Pathol. 2003;162:1951–1960
  41. Dadras SS, Lange-Asschenfeldt B, Velasco P, Nguyen L, Vora A, Muzikansky A, et al. Tumor lymphangiogenesis predicts melanoma metastasis to sentinel lymph nodes. Mod Pathol. 2005;18:1232–1242
  42. Sahni D, Robson A, Orchard G, Szydio R, Evans AV, Russell-Jones R. The use of LYVE-1 antibody for detecting lymphatic involvement in patients with malignant melanoma of known sentinel node status. J Clin Pathol. 2005;58:715–721
  43. Wobser M, Siedel C, Schrama D, Brocker EB, Becker JC, Vetter-Kauczok CS. Expression pattern of the lymphatic and vascular markers VEGFR-3 and CD31 does not predict regional lymph node metastasis in cutaneous melanoma. Arch Dermatol Res. 2006;297:352–357
  44. Straume O, Jackson DG, Akslen LA. Independent prognostic impact of lymphatic vessel density and presence of low-grade lymphangiogenesis in cutaneous melanoma. Clin Cancer Res. 2003;9:250–256
  45. Straume O, Akslen LA. Lymphatic vessel density and prognosis in cutaneous melanoma. Br J Cancer. 2004;91:1224–1225
  46. Evangelos E, Kyzas PA, Trikalinos TA. Comparison of the diagnostic accuracy of lymphatic endothelium markers: Bayesian approach. Mod Pathol. 2005;18:1490–1497
  47. Schacht V, Dadras SS, Johnson LA, Jackson DG, Hong YK, Detmar M. Upregulation of the lymphatic marker podoplanin, a mucin-type transmembrane glycoprotein, in human squamous cell carcinomas and germ cell tumors. Am J Pathol. 2005;66:913–921
  48. Kahn HJ, Marks A. A new monoclonal antibody, D2-40, for detection of lymphatic invasion in primary tumors. Lab Invest. 2002;82:1255–1257
  49. Kahn HJ, Bailey D, Marks A. Monoclonal antibody D2-40, a new marker of lymphatic endothelium, reacts with Kaposi's sarcoma and a subset of angiosarcomas. Mod Pathol. 2002;15:434–440
  50. Niakosari F, Kahn HJ, Marks A, From L. Detection of lymphatic invasion in primary melanoma with monoclonal antibody D2-40: a new selective immunohistochemical marker of lymphatic endothelium. Arch Dermatol. 2005;141:440–444
  51. Arnaout-Alkarain A, Kahn HJ, Narod SA, Sun PA, Marks AN. Significance of lymph vessel invasion identified by the endothelial lymphatic marker D2-40 in node negative breast cancer. Mod Pathol. 2007;20:183–191
  52. Walgenbach-Bruenagel G, Tolba RH, Varnai AD, Bollmann M, Hirner A, Walgenbach KJ. Detection of lymphatic invasion in early stage primary colorectal cancer with the monoclonal antibody D2-40. Eur Surg Res. 2006;38:438–444
  53. Miyakuni Y, Matsumoto T, Arakawa A, Sonoue H, Suzuki C, Takeda S. Lymphatic invasion according to D2-40 immunostaining is a predictor of nodal metastasis in endometrioid adenocarcinoma of the uterine corpus. Pathol Int. 2008;58:471–476
  54. Tomita N, Matsumoto T, Hayashi T, Arakawa A, Sonoue H, Kajiyama Y, et al. Lymphatic invasion according to D2-40 immunostaining is a strong predictor of nodal metastasis in superficial squamous cell carcinoma of the esophagus: algorithm for risk of nodal metastasis based on lymphatic invasion. Pathol Int. 2008;58:282–287
  55. SAS Institute Inc. SAS/STAT® 9.1 User's Guide. Cary (NC): SAS Institute Inc; 2004;
  56. Niakosari F, Kahn HJ, McCready D, Ghazarian D, Rotstein LE, Marks A, et al. Lymphatic invasion identified by monoclonal antibody D2-40, younger age, and ulceration: predictors of sentinel lymph node involvement in primary cutaneous melanoma. Arch Dermatol. 2008;144:462–467
  57. Doeden K, Ma Z, Narasimhan B, Swetter AM, Detmar M, Dadras SS. Lymphatic invasion in cutaneous melanoma is associated with sentinel lymph node metastasis. J Cutan Pathol. 2008 Nov 5;[Epub ahead of print]
  58. Xu X, Gimotty PA, Guerry D, Karakousis G, Van Belle P, Liang H, et al. Lymphatic invasion revealed by multispectral imaging is common in primary melanomas and associates with prognosis. Hum Pathol. 2008;39:901–909

 Supported by a grant from the Stephen Short Memorial Fund from the Department of Dermatology, University of Texas Medical Branch.

 Conflicts of interest: None declared.

 Presented as a poster at the 45th Annual Meeting of the American Society of Dermatopathology, San Francisco, CA, October 16-19, 2008.

PII: S0190-9622(09)00504-0

doi: 10.1016/j.jaad.2009.04.026

Journal of the American Academy of Dermatology
Volume 61, Issue 5 , Pages 819-828 , November 2009

Article Tools

* Image Usage & Resolution